Published: April 13, 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective of new group.

Schlieren, Switzerland – April 18, 2017

The inaugural meeting of the 3D Standards Working Group was held during the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC, on Saturday, April 1.  Organized and hosted by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, and InSphero AG, the meeting drew representatives from academic institutions, pharmaceutical, and life sciences industries, as well as government agencies, to discuss the use of 3D cancer models within drug discovery campaigns, and review biological and technical requirements needed for the next generation of high-throughput screening-compatible (HTS) models.

“There is a growing need for in vitro 3D tumor models that mimic in vivo tumor physiology for more efficient cancer drug discovery,” says InSphero Chief Scientific Officer Dr. Patrick Guye. “We sought to bring together key opinion leaders in academia, industry, and government to develop guidelines that we believe are critical to establishing 3D tumor models as a highly predictive platform for therapeutic drug development assays.” The group plans to publish its findings and recommendations for developing and using 3D tumor models for drug development, with the intent to make the best consensus information available to the broader research community.

“We made tremendous progress during this kickoff meeting,” says Dr. Madhu Lal Nag, Head of the Trans NIH RNAi Facility at NCATS. “We not only discussed where we stand today, with regard to developing advanced 3D models that capture the complexity of the tumor microenvironment, but also delved into needs for standardized nomenclature, benchmarking, improved model predictivity, and multiparametric readouts.” Going forward, the 3D Standards Working Group plans to meet quarterly by teleconference and in person during future conferences, such as AACR, which most members of the working group attend.

For more information about NCATS, visit https://ncats.nih.gov.

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource